Typically, global companies developing innovative therapies are familiar with the differences between regulatory systems in the United States and European Union. In the US, products are regulated by the Food and Drug Administration, which operates under a centralised review and approval framework. In Europe, a hybrid model is used, combining centralised scientific review with national implementation across the different Member States within the EU.
While pre-market pathways receive significant strategic focus, companies often underestimate the differences between the US and European/UK approach to post market regulation. In the US, post-market regulatory obligations continue to be centralised and are overseen by FDA. However, in the EU, regulatory oversight becomes more decentralised, with Member States playing a significant role in implementation and enforcement of their specific post-market requirements.
For regulatory teams supporting global product launches, understanding these structural differences is critical to successful market access. Compliance risk, operational complexity, and lifecycle management obligations can vary significantly depending on how regulatory responsibilities are distributed across jurisdictions.
Comparing Approval Pathways: Centralised FDA Review vs. EU Multi-Route Authorisation
In the United States, the pathway to market for innovative medicines typically runs through a New Drug Application (NDA) or Biologics License Application (BLA), which is submitted to FDA for approval. Scientific review, approval decisions, and post-market oversight all reside within one regulatory agency: FDA. Once approved, the product may be marketed nationwide under one regulatory framework.
The EU offers several authorisation pathways. Innovative medicines are frequently reviewed through the centralised procedure administered by the European Medicines Agency (EMA). This pathway results in a single marketing authorisation valid across all EU Member States (MS).
However, the EU framework also includes decentralised and mutual recognition procedures for certain products. Even under the centralised procedure, Member States maintain authority over various aspects of supervision, implementation, and enforcement following EMA approval.
The practical result is a dual-layer regulatory environment. While the scientific assessment of a product occurs centrally, post-approval regulatory oversight involves the national competent authorities located within each Member State where market access is sought.
This distinction becomes particularly important once products enter the market.
The EU’s Decentralised Post-Market Environment
Just because a product receives marketing authorisation from EMA, it does not translate into centralised market access across the EU. National competent authorities within each individual Member State retain responsibility for regulatory supervision within their jurisdictions. Accordingly, sponsors must interact with multiple regulatory stakeholders after launch to ensure their product is compliant with the specific regulations and requirements unique to each MS where their product is on the market.
Several areas illustrate the operational implications of this structure, particularly labelling governance, promotional oversight, and lifecycle regulatory maintenance.
